Updates on COVID-19 and IBD
Coronavirus and IBD Reporting Database
Welcome to SECURE-IBD!
Surveillance Epidemiology of Coronavirus Under Research Exclusion (SECURE-IBD) is an international, pediatric and adult database to monitor and report on outcomes of COVID-19 occurring in IBD patients. We encourage IBD clinicians worldwide to report ALL cases of COVID-19 in their IBD patients, regardless of severity (including asymptomatic patients detected through public health screening). Reporting a case to this Surveillance Epidemiology of Coronavirus Under Research Exclusion (SECURE)-IBD database should take approximately 5 minutes. Please report only confirmed COVID-19 cases, and report after a minimum of 7 days and sufficient time has passed to observe the disease course through resolution of acute illness or death. To report a case of coronavirus, click here.
With the collaboration of our entire IBD community, we will rapidly be able to define the impact of COVID-19 on patients with IBD and how factors such as age, comorbidities, and IBD treatments impact COVID outcomes.
- This is an international effort—we are counting on robust participation and collaboration.
- We will provide the IBD community with regularly updated summary information about reported cases, including numbers of cases by country, number of cases by treatment, etc. so the entire IBD community has access to these data.
- The database contains only de-identified data, in accordance with HIPAA Safe Harbor De-Identification standards.
- The UNC-Chapel Hill Office for Human Research Ethics has determined that storage and analysis of de-identified data does not constitute human subjects research as defined under federal regulations [45 CFR 46.102 and 21 CFR 56.102] and does not require IRB approval.
We hope you will actively contribute to this voluntary reporting system. Through broad scale participation and collaboration, we will be able to answer these very pressing questions for our IBD patients and their caregivers.
To report a case of coronavirus, click here.
To see our paper in Gastroenterology on characteristics and outcomes of >500 IBD patients from 33 countries with COVID-19, please visit the following link.
If you have any questions, please reach out to COVID.IBD@unc.edu
Michael D. Kappelman, MD, MPH (Pediatric Gastroenterologist, University of North Carolina at Chapel Hill)
Erica J. Brenner, MD (Pediatric Gastroenterology fellow, University of North Carolina at Chapel Hill)
Jean-Frederic Colombel, MD (Gastroenterologist, Icahn School of Medicine at Mount Sinai, New York)
Ryan Ungaro, MD, MS (Gastroenterologist, Icahn School of Medicine at Mount Sinai, New York)
Manasi Agrawal, MD (Gastroenterologist, Icahn School of Medicine at Mount Sinai, New York)
International Advisory Committee Members
Asia: Dr. Siew Ng MBBS, PhD, FRCP, AGAF, FHKCP, FHKAM (the Chinese University of Hong Kong)
Australia/New Zealand: Dr. Richard Gearry, MBChB (the University of Otago)
Europe: Dr. Walter Reinisch, MD (Medical University of Vienna) and Dr. Jean-Francois Rahier, MD, PhD (CHU UCL Namur, site Godinne)
North America: Dr. James Lewis, MD, MSCE (the University of Pennsylvania) and Dr. Gilaad Kaplan, MD, MPH, FRCPC (the University of Calgary)
South America: Dr. Flavio Steinwurz, MD, MSc, MACG (Albert Einstein Jewish Hospital)
Nursing and Advanced Practitioners: Michele Kissous-Hunt, PA-C, DFAAPA (Fifth Avenue GI)
Industry: Dr. Irene Modesto, MD, PhD (Pfizer)
IOIBD: Marishka Konings (Secretariat IOIBD)
NOTE: If your patient is pregnant, please note that in the Case Report Form (under other comorbidities) and kindly refer them to the PIANO registry for pregnant women with IBD